

Validation of the MycoTOOL Mycoplasma Real-Time PCR Kit

Sebastian Weber[†], Raphael Greiner[†], Alexander Bartes[‡], Holger Kavermann[‡], Yvonne Knack[‡], Sven Deutschmann[‡]



[†]Roche CustomBiotech, Mannheim, Germany
[‡]Roche Pharma Biotech, Penzberg, Germany
Address correspondence to: custombiotech.ussales@roche.com

Abstract

Mycoplasma contamination of biopharmaceuticals – as a consequence of cell culture contamination in the manufacturing process – poses a potential health risk to patients¹. To minimize this risk, regulatory agencies require manufacturers of biopharmaceuticals to ensure the absence of mycoplasmas in the manufacturing process and end product²⁻⁶. To test for mycoplasmas, key regulatory guidelines, such as EP2.6.7², USP<63>³, and JP⁴, have in the past recommended protocols that relied exclusively on the culture method or indicator cell culture method. These protocols suffer from several limitations, such as lengthy overall testing time (28 days) and difficult-to-cultivate or non-cultivable mycoplasma species. Hence, many regulatory agencies now additionally accept rapid nucleic acid amplification techniques (NAT) such as real-time quantitative polymerase chain reaction (qPCR) for mycoplasma testing. The MycoTOOL Mycoplasma Real-Time PCR Kit (MycoTOOL RT) is a commercially available qPCR assay developed in-house by Roche Pharma that has now been validated according to the EP2.6.7 NAT validation guidelines². In the following, we present the MycoTOOL RT workflow and validation results. The full validation report is available upon request and under confidential disclosure agreement.



Figure 1. The MycoTool RT assay allows mycoplasma testing anytime during the production process, which may then be aborted to save costs in case of contamination. Regulatory agencies require testing during the harvest, as indicated by the arrow.

1 – MycoTOOL RT Kit Design




Figure 2. MycoTOOL RT workflow using either a manual or automated DNA extraction method. The automated workflow based on the MagNA Pure 96 and LightCycler[®] 480 II systems shown as the red-marked process has been fully validated by Roche Pharma Biotech as it is presented in this poster. *Both the MagNA Pure 24 system and the QC Preparation Kit are functionally tested, but not validated.

Control Concept

MycoTOOL RT uses the following fluorescent dyes to detect mycoplasma DNA and a recovery control plasmid, respectively: fluorescein amidite (FAM), and Yellow 555. All controls are included in the MycoTOOL RT Kit.

Each biological sample to be tested for mycoplasma contamination requires the following separate qPCR reactions on a 96-well PCR plate:

1. Cell sample spiked with recovery control plasmid prior to DNA

3. Robustness

We spiked 10 CHO cell culture samples with *M. orale* at a concentration three times higher than the calculated LOD and performed the MycoTOOL RT assay using at least two different manufacturing batches of the kit.

Acceptance criteria by EP2.6.7 were met if:

- All spiked samples gave positive results
- The mean of all samples was within a range of 4 $\ensuremath{C_{\text{q}}}$ values

4. Precision

Three different analysts spiked 8 CHO cell culture samples with 1.5 CFU/mL *M. orale* and performed the MycoTOOL RT assay on different days.

Acceptance criteria by EP2.6.7 were met if:

- · All spiked samples gave a positive result for each analyst
- The mean of all samples was within a range of 4 C_a values

5. Cross-Contamination

We spiked 10 CHO cell culture samples with *M. orale* at a concentration 100 times higher than the calculated LOD and prepared 10 unspiked CHO cell samples. We performed the MycoTOOL RT assay with all samples. The spiked and unspiked samples were placed alternately on the microtiter plate of the MagNA Pure 96 system for DNA isolation as well as on the multiwell plate of the LightCycler[®] 480 II system for qPCR.

Acceptance criteria by EP2.6.7 were met if:

• All spiked samples gave positive results and all unspiked samples gave negative results

6. Comparability

We performed comparability studies to show equivalency between the two compendial methods and the MycoTOOL RT assay. We spiked a 15 mL preharvest CHO cell culture sample with mollicute reference strains (Table 4). The spike was performed in tenfold dilution series ranging from 100 – 0.001 CFU/mL. MycoTOOL RT and the two compendial methods were performed in triplicates for all samples.

Acceptance criteria by EP2.6.7 were met if:

2. Specificity

Cross-detection was observed for *L. acidophilus* above a spike concentration of 10⁴ CFU/mL, for *S. bovis* above 10⁶ CFU/mL and *C. sporogenes* above 10² CFU/mL.

3. Robustness

10 out of 10 *M. orale* dilutions were successfully detected for each MycoTOOL RT manufacturing batch. The ΔC_q between runs was 0.04.

4. Precision

All *M. orale* dilutions gave a positive result and the ΔC_q between runs was 1.93 (Table 3).

		Analyst 1	Analyst2	Analyst3
PCR result	mycoplasma (<i>M. orale</i>)	8/8	8/8	8/8
	recovery control	8/8	8/8	8/8
ØCq (mycoplasma: <i>M. orale</i>)		38.89	37.00	38.93
ΔCq (mycoplasma: <i>M. orale</i>)		1.93		

Table 3. Test results to determine the precision of the MycoTOOL RT assay

5. Cross-contamination

All *M. orale* spiked samples yielded positive results (10 out of 10) and all unspiked samples yielded negative results (10 out of 10). Thus, we detected no cross-contamination during the whole workflow.

6. Comparability

Results of the comparability study are summarized in Table 4. We concluded that all three methods are sensitive methods to detect mycoplasma contaminations with a sensitivity ≤ 10 CFU/mL. In addition, MycoTOOL RT is able to detect strains that are non-cultivable.

Mallioute		DetectionLimit			
Mollicute Species	Source	Culture Method [CFU/mL]	Indicator Cell Culture Method [CFU/mL]	MycoTOOLRT [CFU/mL]	
M. hominis	ATCC 23114	1	0.1	0.1	
M. orale	ATCC 23714	0.1	ND	1	
M. aginini	ATCC 23838	0.01	1	1	
A. laidlawii	EDQM	0.01	0.1	0.1	
M. hyorhinis	EDQM	1	1	10	
M. pneumoniae	NCTC 10119	1	ND	1	
M. salivarium	ATCC 23064	0.1	ND	0.1	
M. fermentans	ATCC 19989	10	1	0.1	
Sp. <i>citri</i>	ATCC 27556	ND	ND	0.1	
M. hyorhinis*	ATCC 29052	ND	1	10	
* Fastidious strain		ND= not detectable			

- preparation (4 technical replicates [rxn] per fluorescent dye)
- 2. Plasmid containing mycoplasma DNA (positive PCR control; 4 rxn)
- 3. Water (negative PCR control; 2 rxn per fluorescent dye)
- 4. Mycoplasma-free cell sample spiked with recovery control plasmid prior to DNA preparation (negative process control; 4 rxn per fluorescent dye)

2 – Materials and Methods

Materials - Mammalian and Mycoplasma Cells

For each sample, we used 5 x 10^6 cells/mL of a standard CHO cell culture that had been confirmed to be mycoplasma-free in fourfold determination. We obtained stocks of ten different mollicute reference strains from three different sources and determined their genomic copy per colony forming units (GC/CFU) ratio using an in-house method (Table 1). The mollicute strains chosen represent all strains required by the EP2.6.7² and additionally include *M. orale, M. salivarium* and *M. hominis*.

Validation Design

The validation of MycoTOOL RT followed the criteria as mentioned in the EP2.6.7² and ICH-Q2 R1⁷ guidelines:

1. Limit of Detection (LOD)

We spiked CHO cell culture samples with each mollicute reference strain (Table 2) in a dilution series ranging from 10 - 0.1 CFU/mL. The MycoTOOL RT assay was run in eightfold determination and repeated on three different days, yielding 24 results per dilution. The LOD was defined as the lowest number of CFU that could be detected in 23 out of 24 samples.

Acceptance criteria by EP2.6.7 were met if:

• The LOD was $\leq 10 \text{ CFU/mL}$

2. Specificity

We spiked CHO cell culture samples with three gram-positive bacterial species (*Streptococcus bovis, Lactobacillus acidophilus, Clostridium sporogenes*) in a tenfold dilution series ranging from 10⁶ – 10² CFU/mL. The MycoTOOL RT assay was run in eightfold determination and repeated on three different days, yielding 24 results per dilution.

Acceptance criteria by EP2.6.7 were met if:

- The spiked samples showed a qPCR quantification cycle (C_q) value at or above the respective calculated LOD of Table 1

· MycoTOOL RT was at least as sensitive as the compendial test methods

3 – Results

Determination of GC/CFU Ratio

To ensure that the viability of the mollicute reference strains is sufficiently high, a GC/CFU ratio of \leq 100 is recommended⁸. All tested mollicute reference strains showed GC/CFU ratios < 100 (Table 1).

Mollicute Species	Source	Total Mean GC/CFU Ratio (n=3)
M. hominis	ATCC 23114	59.1
M. orale	ATCC 23714	74.2
M. aginini	ATCC 23838	25.4
A. laidlawii	EDQM	30.3
M. hyorhinis	EDQM	8.1
M. hyorhinis*	ATCC 29052	0.7
M. pneumoniae	NCTC 10119	11.6
M. salivarium	ATCC 23064	7.3
M. fermentans	ATCC 19989	36.2
Sp. <i>citri</i>	ATCC 27556	51.8

Table 1. GC/CFU ratios for mollicute reference strains.

Validation Results

General acceptance criteria for MycoTOOL RT results were that all positive controls gave positive signals and all negative controls gave negative signals. Thus a sample was regarded as truly positive or negative only if all controls yielded the expected signals.

1. <u>LOD</u>

The LOD was determined to be \leq 10 CFU/mL for each mycoplasma reference strain (Table 2). The data confirm that MycoTOOL RT is a highly sensitive detection method.

Mollicute Species	Source	LOD [CFU/mL]	
M. hominis	ATCC 23114	0.2	
M. orale	ATCC 23714	5.0	
M. aginini	ATCC 23838	0.3	
A. laidlawii	EDQM	0.1	
M. hyorhinis	EDQM	2.0	
M. pneumoniae	NCTC 10119	7.0	
M. salivarium	ATCC 23064	3.0	
M. fermentans	ATCC 19989	0.2	
Sp. citri	ATCC 27556	0.1	
M. hyorhinis*	ATCC 29052	10.0	

Table 4. Comparison between the different mycoplasma detection methods.

4 – Summary and Discussion

This validation study demonstrates the compliance of MycoTOOL RT with the EP2.6.7² NAT validation guideline. The results demonstrate that MycoTOOL RT is sensitive, specific, robust, precise, and comparable to the compendial mycoplasma methods. Thus, it fulfills all requirements as given by EP2.6.7² to detect mycoplasma contamination during CHO manufacturing processes of biopharmaceuticals. Like Roche Pharma Biotech Penzberg in Germany manufacturers of biopharmaceuticals are moving towards rapid NAT methods and we believe that this trend will continue in the future.

5 – References

- 1) Volokhov DV et al. Mycoplasma testing of cell substrates and biologics: Review of alternative non-microbiological techniques. Mol Cell Probes 2011; 25: 69-77
- 2) Council of Europe. European Pharmacopoeia, 9th ed. Chapter 2.6.7: Mycoplasmas. Strasbourg, France; 2017
-) United States Pharmacopeial Convention. United States Pharmacopeia National Formulary (USP-NF), 39th ed. Chapter 63: Mycoplasma Tests; Rockville, MD, USA; 2016
- Ministry of Health, Labour and Welfare. Japanese Pharmacopoeia, 17th ed. Mycoplasma testing for cell substrates used for the production of biotechnological/biological products. Tokyo, Japan; 2016
- International Committee on Harmonization. Q5D: Derivation and characterization of cell substrates used for production of biotechnological/biological products. Geneva, Switzerland; 1997
- 6) Food and Drug Administration. Points to consider in the characterization of cell lines used to produce biologicals. Rockville, MD, USA; 1993
- 7) ICH Expert Working Group, ICH Q2(R1) Validation of Analytical Procedures: Text and Methodology, Geneva, Switzerland; 2005
- Dabrazhynetskaya A et al. Preparation of reference strains for validation and comparison of mycoplasma testing methods. J Appl Microbiol 2011;111:904-914

